Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1979 Nov;64(5):1393–1401. doi: 10.1172/JCI109597

Exposure of platelet fibrinogen receptors by ADP and epinephrine.

J S Bennett, G Vilaire
PMCID: PMC371288  PMID: 574143

Abstract

The role of fibrinogen as a cofactor for platelet aggregation was examined by measuring the binding of 125I-labeled human fibrinogen to gel-filtered human platelets both before and after platelet stimulation by ADP and epinephrine. Platelet stimulation by ADP resulted in the rapid, reversible binding of fibrinogen to receptors on the platelet surface. Fibrinogen binding increased as the concentration of ADP was increased from 0.1 to 2 microM, reaching a plateau at higher ADP concentrations. Binding occurred only after platelet stimulation and in the presence of divalent cations. However, fibrinogen binding did not occur to ADP-stimulated platelets from three patients with Glanzmann's thrombasthenia. Analysis of fibrinogen binding as a function of increasing fibrinogen concentration demonstrated that maximal platelet stimulation exposed approximately or equal to 45,000 binding sites per platelet with a dissociation constant of 80--170 nM. These fibrinogen binding parameters were essentially the same whether ADP or epinephrine was the platelet-stimulating agent. Thus, these studies demonstrate that platelet stimulation by ADP and epinephrine exposes a limited number of fibrinogen receptors on the platelet surface. Furthermore, these data suggest that the fibrinogen molecules bound to the platelet as a consequence of platelet stimulation are directly involved in the platelet aggregation response.

Full text

PDF
1393

Images in this article

1395Image
on p.1395

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allain J. P., Cooper H. A., Wagner R. H., Brinkhous K. M. Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor. J Lab Clin Med. 1975 Feb;85(2):318–328. [PubMed] [Google Scholar]
  2. BORN G. V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962 Jun 9;194:927–929. doi: 10.1038/194927b0. [DOI] [PubMed] [Google Scholar]
  3. Bennett J. S., Colman R. F., Colman R. W. Identification of adenine nucleotide binding proteins in human platelet membranes by affinity labeling with 5'-p-flurosulfonylbenzoyl adenosine. J Biol Chem. 1978 Oct 25;253(20):7346–7354. [PubMed] [Google Scholar]
  4. Broekman M. J., Handin R. I., Cohen P. Distribution of fibrinogen, and platelet factors 4 and XIII in subcellular fractions of human platelets. Br J Haematol. 1975 Sep;31(1):51–55. doi: 10.1111/j.1365-2141.1975.tb00831.x. [DOI] [PubMed] [Google Scholar]
  5. Catt K. J., Dufau M. L. Peptide hormone receptors. Annu Rev Physiol. 1977;39:529–557. doi: 10.1146/annurev.ph.39.030177.002525. [DOI] [PubMed] [Google Scholar]
  6. Cheng Y., Prusoff W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec 1;22(23):3099–3108. doi: 10.1016/0006-2952(73)90196-2. [DOI] [PubMed] [Google Scholar]
  7. Coller B. S. The effects of ristocetin and von Willebrand factor on platelet electrophoretic mobility. J Clin Invest. 1978 May;61(5):1168–1175. doi: 10.1172/JCI109032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Degos L., Dautigny A., Brouet J. C., Colombani M., Ardaillou N., Caen J. P., Colombani J. A molecular defect in thrombasthenic platelets. J Clin Invest. 1975 Jul;56(1):236–240. doi: 10.1172/JCI108074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Doolittle R. F. Structure and function of fibrinogen. Horiz Biochem Biophys. 1977;3:164–191. [PubMed] [Google Scholar]
  10. Galanakis D. K., Mosesson M. W., Stathakis N. E. Human fibrinogen heterogeneities: distribution and charge characteristics of chains of A alpha origin. J Lab Clin Med. 1978 Sep;92(3):376–386. [PubMed] [Google Scholar]
  11. Harker L. A., Slichter S. J. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med. 1972 Jul 27;287(4):155–159. doi: 10.1056/NEJM197207272870401. [DOI] [PubMed] [Google Scholar]
  12. Hawiger J., Hammond D. K., Timmons S., Budzynski A. Z. Interaction of human fibrinogen with staphylococci: presence of a binding region on normal and abnormal fibrinogen variants and fibrinogen derivatives. Blood. 1978 May;51(5):799–812. [PubMed] [Google Scholar]
  13. IZZO J. L., BALE W. F., IZZO M. J., RONCONE A. HIGH SPECIFIC ACTIVITY LABELING OF INSULIN WITH 131-I. J Biol Chem. 1964 Nov;239:3743–3748. [PubMed] [Google Scholar]
  14. Jerushalmy Z., Zucker M. B. Some effects of fibrinogen degradation products (FDP) on blood platelets. Thromb Diath Haemorrh. 1966 May 15;15(3):413–419. [PubMed] [Google Scholar]
  15. LOEWY A. G., DUNATHAN K., KRIEL R., WOLFINGER H. L., Jr Fibrinase. I. Purification of substrate and enzyme. J Biol Chem. 1961 Oct;236:2625–2633. [PubMed] [Google Scholar]
  16. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  17. Levy-Toledano S., Tobelem G., Legrand C., Bredoux R., Degos L., Nurden A., Caen J. P. Acquired IgG antibody occurring in a thrombasthenic patient: its effect on human platelet function. Blood. 1978 Jun;51(6):1065–1071. [PubMed] [Google Scholar]
  18. Lipinska I., Lipinski B., Gurewich V. Fibrinogen heterogeneity in human plasma. Electrophoretic demonstration and characterization of two major fibrinogen components. J Lab Clin Med. 1974 Oct;84(4):509–516. [PubMed] [Google Scholar]
  19. Marguerie G., Chagniel G., Suscillon M. The binding of calcium to bovine fibrinogen. Biochim Biophys Acta. 1977 Jan 25;490(1):94–103. doi: 10.1016/0005-2795(77)90109-x. [DOI] [PubMed] [Google Scholar]
  20. Marguerie G. The binding of calcium to fibrinogen: some structural features. Biochim Biophys Acta. 1977 Sep 27;494(1):172–181. doi: 10.1016/0005-2795(77)90145-3. [DOI] [PubMed] [Google Scholar]
  21. Miller J. L., Katz A. J., Feinstein M. B. Plasmin inhibition of thrombin-induced platelet aggregation. Thromb Diath Haemorrh. 1975 Apr 30;33(2):286–309. [PubMed] [Google Scholar]
  22. Mustard J. F., Packham M. A., Kinlough-Rathbone R. L., Perry D. W., Regoeczi E. Fibrinogen and ADP-induced platelet aggregation. Blood. 1978 Aug;52(2):453–466. [PubMed] [Google Scholar]
  23. Niewiarowski S., Budzynski A. Z., Lipinski B. Significance of the intact polypeptide chains of human fibrinogen in ADP-induced platelet aggregation. Blood. 1977 Apr;49(4):635–644. [PubMed] [Google Scholar]
  24. O'Brien J. R. Effects of adenosine diphosphate and adrenaline on mean platelet shape. Nature. 1965 Jul 17;207(994):306–307. doi: 10.1038/207306b0. [DOI] [PubMed] [Google Scholar]
  25. Phillips D. R., Agin P. P. Platelet membrane defects in Glanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins. J Clin Invest. 1977 Sep;60(3):535–545. doi: 10.1172/JCI108805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Rodbard D., Feldman H. A. Theory of protein-ligand interaction. Methods Enzymol. 1975;36:3–16. doi: 10.1016/s0076-6879(75)36003-5. [DOI] [PubMed] [Google Scholar]
  27. Seaman G. V., Vassar P. S. Changes in the electrokinetic properties of platelets during their aggregation. Arch Biochem Biophys. 1966 Oct;117(1):10–17. doi: 10.1016/0003-9861(66)90119-6. [DOI] [PubMed] [Google Scholar]
  28. Tangen O., Berman H. J., Marfey P. Gel filtration. A new technique for separation of blood platelets from plasma. Thromb Diath Haemorrh. 1971 Jun 30;25(2):268–278. [PubMed] [Google Scholar]
  29. Tangen O., McKinnon E. L., Berman H. J. On the fine structure and aggregation requirements of gel filtered platelets (GFP). Scand J Haematol. 1973;10(2):96–105. doi: 10.1111/j.1600-0609.1973.tb00046.x. [DOI] [PubMed] [Google Scholar]
  30. Tollefsen D. M., Majerus P. W. Inhibition of human platelet aggregation by monovalent antifibrinogen antibody fragments. J Clin Invest. 1975 Jun;55(6):1259–1268. doi: 10.1172/JCI108045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Weber K., Osborn M. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem. 1969 Aug 25;244(16):4406–4412. [PubMed] [Google Scholar]
  32. Weiss H. J. Platelet physiology and abnormalities of platelet function (first of two parts). N Engl J Med. 1975 Sep 11;293(11):531–541. doi: 10.1056/NEJM197509112931105. [DOI] [PubMed] [Google Scholar]
  33. Weiss H. J., Rogers J. Fibrinogen and platelets in the primary arrest of bleeding. Studies in two patients with congenital afibrinogenemia. N Engl J Med. 1971 Aug 12;285(7):369–374. doi: 10.1056/NEJM197108122850703. [DOI] [PubMed] [Google Scholar]
  34. Zimmerman T. S., Ratnoff O. D., Powell A. E. Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's dissase, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest. 1971 Jan;50(1):244–254. doi: 10.1172/JCI106480. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES